Preclinical study demonstrates that levistilide A triggers ferroptosis to curb colorectal cancer lung metastasis via RNF40-mediated HSP90α degradation, indicating a promising therapeutic target.
The molecular mechanisms underlying lung metastasis of colorectal cancer (CRC) remain largely elusive, and effective therapeutic agents are still lacking. In this study, we identify levistilide A (LeA) as a potential anti-metastatic agent against CRC lung metastasis. We demonstrate that heat shock protein 90α (HSP90α) is markedly upregulated in CRC and promotes lung metastasis by suppressing ferroptosis. Notably, combined treatment with LeA and the ferroptosis inducer RSL3 further alleviates lung metastatic burden in vivo. Mechanistically, we reveal that the E3 ubiquitin ligase ring finger protein 40 (RNF40) suppresses CRC cell proliferation by directly interacting with HSP90α, inducing ubiquitination at lysine 407 and promoting its proteasomal degradation. RNF40-mediated HSP90α downregulation leads to the accumulation of malondialdehyde (MDA) and reactive oxygen species (ROS), thereby inhibiting CRC cell growth. Collectively, our findings provide mechanistic insights into how LeA directly targets HSP90α or facilitates RNF40-HSP90α-mediated degradation of HSP90α to regulate ferroptosis in CRC.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: